Taming the Notch Transcriptional Regulator for Cancer Therapy

• Main Authors: Luca Tamagnone, Serena Zacchigna, Michael Rehman
• Format: Article
• Language: English
• Published: MDPI AG 2018-02-01
• Series: Molecules
• Subjects: Notch transcription complex; gamma secretase inhibitors; combination therapy; blocking antibody; clinical trials
• Online Access: http://www.mdpi.com/1420-3049/23/2/431

Notch signaling is a highly conserved pathway in all metazoans, which is deeply involved in the regulation of cell fate and differentiation, proliferation and migration during development. Research in the last decades has shown that the various components of the Notch signaling cascade are either upregulated or activated in human cancers. Therefore, its downregulation stands as a promising and powerful strategy for cancer therapy. Here, we discuss the recent advances in the development of small molecule inhibitors, blocking antibodies and oligonucleotides that hinder Notch activity, and their outcome in clinical trials. Although Notch was initially identified as an oncogene, later studies showed that it can also act as a tumor suppressor in certain contexts. Further complexity is added by the existence of numerous Notch family members, which exert different activities and can be differentially targeted by inhibitors, potentially accounting for contradictory data on their therapeutic efficacy. Notably, recent evidence supports the rationale for combinatorial treatments including Notch inhibitors, which appear to be more effective than single agents in fighting cancer.